Fabry disease Trials in Parkville, Australia
Conditions / Fabry disease / Parkville, Australia
Fabry disease is a medical condition with active clinical research programs worldwide.
20 total trials for this combination
Showing top 10 of 20 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04046224 | Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) | COMPLETED | — |
| NCT03425539 | Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease | COMPLETED | PHASE3 |
| NCT03566017 | Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease | COMPLETED | PHASE3 |
| NCT03737214 | A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05206773 | A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00925301 | Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease | COMPLETED | PHASE3 |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | RECRUITING | — |
| NCT02194985 | Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease | COMPLETED | PHASE3 |
| NCT01218659 | Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease | COMPLETED | PHASE3 |
| NCT01458119 | Open-Label Phase 3 Long-Term Safety Study of Migalastat | TERMINATED | PHASE3 |